Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.
You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings
A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.
5/18/2020
Grünenthal considers the outbreak and spread of Covid-19 (known as new coronavirus) to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees, ensuring an uninterrupted supply of our medicines for patients, and supporting communities with curbing the Covid-19 outbreak.
11/29/2019
Zur Zeit wird in den Medien berichtet, dass die Conterganstiftung beabsichtigt, die Zahlungen an brasilianische Betroffene, die durch das Produkt "Sedalis" geschädigt wurden, einzustellen. Wir nehmen wie folgt Stellung:
11/29/2019
We have recorded numerous media reports about the intent of the German Contergan Foundation to cease payments to people affected by "Sedalis". Grünenthal's position on this matter is as follows:
Štěpán Kráčala
Head Global Communications
Grünenthal GmbH
52099
Germany
Phone +49 241 569-1335